Clinical trials: Phosphorus
X-linked Hypophosphatemia (XLH)
Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Paediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia…
- Trial name
- NCT04188964
- Testing
- Burosumab
- Where
- 9 sites in Austria, France and 4 more
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
X-linked Hypophosphatemia
Using Different Doses of Active Vitamin D Combined With Neutral Phosphate in Children With X-linked Hypophosphatemia
X-linked hypophosphatemia (XLH) is the most common form of heritable rickets. Current treatments include active vitamin D metabolites (e.g. calcitriol) and phosphate salts.
- Trial name
- NCT03820518
- Testing
- Calcitriol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Chronic Kidney Disease, Dialysis
Long-term Extension Study of MCI-196
The Primary Objectives of this study are to assess the long-term efficacy of treatment with colestilan (MCI-196) (including combination therapy) and to assess the long-term safety of treatment with colestilan (MCI-196) (including…
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia, Paediatric
- Trial name
- NCT01814917
- Testing
- colestilan, CBPB
- Where
- United Kingdom
- Volunteers
- 6 people
- Sponsor
- Tanabe Pharma Corporation
White Spot Lesion of Tooth
RMGI Varnish Versus APF Gel in Prevention of White Spot Lesions During Orthodontic Treatment
evaluate the effect of a single application of Clinpro XT varnish on enamel demineralization adjacent to orthodontic brackets during fixed orthodontic treatment in comparison with acidulated phosphorus fluoride gel.
- Trial name
- NCT03721198
- Testing
- Acidulated phosphorous flouride, Resin modified glass ionomer varnish
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mohamed zidan
Malnutrition
Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.
Fibroblast growth factor 23 (FGF23) is a recently discovered phosphaturic hormone produced by osteocytes. It is involved in phosphate-calcium metabolism (via its phosphaturic action and inhibition of 1,25-OH vitamin D).
- Trial name
- IPSAASU (NCT02812134)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
X-Linked Hypophosphatemia
Registry for Patients With X-Linked Hypophosphatemia
This is an international, multicentre, prospective, non-interventional, observational Registry of patients with X-Linked hypophosphatemia (XLH).
- Trial name
- NCT03193476
- Where
- 118 sites in Belgium, Bulgaria and 18 more
- Volunteers
- 1,489 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Hypophosphatemia, Rickets
The Impact of Phosphate Metabolism on Healthy Aging
Determine the association between duration and dose of chronic conventional therapy with Pi and renal (nephrocalcinosis/nephrolithiasis), vascular (endothelial function), and cardiovascular function (echo- cardiography) in…
- Conditions
- Hypophosphatemia, Rickets, Hypercalciuria, XLH
- Trial name
- NCT03771105
- Testing
- phosphate
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Autosomal Dominant Hypophosphatemic Rickets
Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.
The purpose of the study is to gain a better understanding of the effect of iron on fibroblast growth factor 23 (FGF23) in the inherited disorder, autosomal dominant hypophosphatemic rickets (ADHR).
- Trial name
- NCT02233322
- Testing
- Iron
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Indiana University
Hypophosphatemic Rickets
Milk Products in the Treatment of Hypophosphatemic Rickets
The aim of this study was to investigate the feasibility and efficacy of a high intake of milk and/or cheese products compared to phosphate tablets in patients with hypophosphatemic rickets when evaluating the S-phosphate levels…
- Trial name
- NCT03348644
- Testing
- Phosphate tablets., High cheese intake., High milk intake.
- Where
- Denmark
- Volunteers
- 7 people
- Sponsor
- University of Aarhus
Phosphate Deficiency, Phosphate Overload
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism
The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by diseases of phosphate metabolism, aimed at collecting and studying anamnestic, diagnostic, genetic…
- Trial name
- NCT06826664
- Where
- 28 sites in Italy
- Volunteers
- 100 people
- Sponsor
- F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
X-linked Hypophosphatemia
Foot Disorders in X-linked Hypophosphatemia
This study aimed to characterize foot pathologies using X-rays and clinical examination and assess related outcome scores in adolescents and adults with X-linked Hypophophatemia
- Trial name
- NCT06067932
- Testing
- Foot X rays, Clinical examination + scores
- Where
- Austria
- Volunteers
- 28 people
- Sponsor
- Orthopedic Hospital Vienna Speising
X-linked Hypophosphatemia, Tumor-Induced Osteomalacia
Expanded Access to Burosumab
Individual patient expanded access requests may be considered for patients who have no other treatment options
- Trial name
- NCT03775187
- Testing
- Burosumab
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Kidney Diseases, Hyperphosphatemia
Improving Phosphate Control in Children With CKD
Research goals: To explore the views and baseline knowledge of children and young people (CYP) with CKD and their caregivers to develop effective phosphate educational materials (PEM), adapted for age, and acknowledging different…
- Conditions
- Chronic Kidney Diseases, Hyperphosphatemia, Pediatric Kidney Disease, CKD-MBD
- Trial name
- IMPACT (NCT05439980)
- Testing
- Knowledge questionnaire, Focus groups
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Infant, Premature, Diseases
Calcium (ca),Phosphorus( P) and 25-hydroxyvitamin D(25OHD)] in Infants Born ≤ 32 PMA Gestational Weeks (GA)
It has not yet been established the optimal dose of vit. D for preterm infants in Poland. It is not known what dose of vit. D will provide the correct concentration of vit.
- Trial name
- Ca-P (NCT03691896)
- Testing
- Cholecalciferol 400, Cholecalciferol 800, Cholecalciferol 1200
- Where
- Poland
- Volunteers
- 200 people
- Sponsor
- Centre of Postgraduate Medical Education
Hypophosphatemia, Familial, Rickets
Hypophosphatemic Rickets in Norway
The purpose of the study is to do a follow-up survey of all individuals with hereditary hypophosphatemia in Norway, focusing on manifestations in childhood and adolescence.
- Conditions
- Hypophosphatemia, Familial, Rickets, Hyperphosphatemia
- Trial name
- NCT01057186
- Testing
- Alfacalcidol; phosphate., Sevelamer
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Haukeland University Hospital
Chronic Kidney Disease, Dialysis
A Study of MCI-196 in Chronic Kidney Disease Stage V Subjects on Dialysis With Hyperphosphatemia
This is a PIII multi-center, open-label, flexible dose, long-term safety study, that in conjunction with the E07(NCT00416520), E08(NCT00542386) and E09(NCT00451295) studies will allow exposure to MCI-196 for up to 52 weeks
- Conditions
- Chronic Kidney Disease, Dialysis, Hyperphosphatemia
- Trial name
- NCT00542815
- Testing
- MCI-196, Another Phosphate binder (Sevelamer)
- Where
- 115 sites in Austria, Czechia and 13 more
- Volunteers
- 632 people
- Sponsor
- Tanabe Pharma Corporation
Hyperphosphatemia
Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients
Transition to Ferric Citrate among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 "Real World" Experience Study from Kaiser Permanente Southern California
- Trial name
- NCT03079869
- Testing
- Ferric Citrate
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Kaiser Permanente
Phosphate Deficiency, Covid19
The Effect of COVID-19 Patients' Serum Phosphate Level on Mortality in ICU
The investigators aimed to investigate the relationship between phosphate level and mortality using the 4C Mortality Score in COVID-19 patients who were followed up in the intensive care unit.
- Conditions
- Phosphate Deficiency, Covid19, Mortality
- Trial name
- NCT04800770
- Testing
- 4C mortality score
- Where
- Turkey (Türkiye)
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Ankara City Hospital Bilkent